GCP
TTNP

GSA Capital Partners’s Titan Pharmaceuticals TTNP Stock Holding History

GSA Capital Partners’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,991
Closed -$119K – 1606
2021
Q1 		$119K Buy
+1,991
New +$132K 0.02% 987
2017
Q1 		– Sell
-18
Closed -$260K – 1998
2016
Q4 		$260K Buy
+18
New +$303K 0.02% 1421

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GSA Capital Partners's TTNP Position: Q2 2021 in Review

GSA Capital Partners sold out of Titan Pharmaceuticals (TTNP) in Q2 2021, closing a stake of 1,991 shares — an estimated $119K sold.

GSA Capital Partners first reported a position in TTNP in Q4 2016 and held it in 2 quarters. The position peaked at $260K in Q4 2016. 16 funds tracked by Wall St. Rank hold TTNP as of Q2 2021.

  • GSA Capital Partners reported no remaining Titan Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • GSA Capital Partners sold 1,991 Titan Pharmaceuticals shares in Q2 2021, an estimated $119K.
  • GSA Capital Partners first reported a position in Titan Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • GSA Capital Partners's Titan Pharmaceuticals position peaked at $260K in Q4 2016.
  • 16 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2021.

Based on GSA Capital Partners's 13F filing for Q2 2021, filed 5 Aug 2021.